Introduction {#sec1}
============

Neuropsychiatric symptoms (NPS) associated with dementia are common in long-term care (LTC) settings with approximately 80% of individuals with dementia in LTC exhibiting NPS at any time (Zuidema *et al*., [@ref112]; Seitz *et al*., [@ref83]). Guidelines (Canadian Coalition for Seniors' Mental Health, [@ref17]; Herrmann *et al*., [@ref42]) and previous reviews (Sink *et al*., [@ref88]) have emphasized the importance of comprehensive assessment to rule out pain (Cohen-Mansfield and Mintzer, [@ref21]; Sink *et al*., [@ref88]), delirium (Sink *et al*., [@ref88]), and environmental or interpersonal factors (Sink *et al*., [@ref88]) which may precipitate behaviors. Non-pharmacological interventions are usually recommended as first-line treatments for NPS. Unfortunately, knowledge of psychosocial interventions in LTC is low (Cohen-Mansfield and Jensen, [@ref19]), access to services for these interventions is limited (Conn, [@ref24]; Burns *et al*., [@ref16]; Meeks, [@ref60]; Reichman *et al*., [@ref72]; Seitz *et al*., [@ref84]), their effectiveness may be modest (Seitz *et al*., [@ref85]), and patients may not cooperate with these interventions (Cohen-Mansfield *et al*., [@ref23]). Therefore, there remains a potential role for medications in managing NPS in LTC.

Psychotropic medications are frequently prescribed in LTC (Gruber-Baldini *et al*., [@ref37]; Pitkala *et al*., [@ref67]; Selbaek *et al*., [@ref86]). The estimated prevalence of the use of these medications among LTC residents with dementia is 25%--40% for antipsychotics (Pitkala *et al*., [@ref67]; Rochon *et al*., [@ref73]; Selbaek *et al*., [@ref87]; Nijk *et al*., [@ref64]; Larrayadieu *et al*., [@ref58]; Snowdon *et al*., [@ref90]), 25%--30% for antidepressants (Pitkala *et al*., [@ref67]; Nijk *et al*., [@ref64]; Snowdon *et al*., [@ref90]), cognitive enhancers in 25%--30% (Seitz *et al*., [@ref82]), and benzodiazepines in 15%--30% (Pitkala *et al*., [@ref67]; Selbaek *et al*., [@ref87]; Nijk *et al*., [@ref64]; Snowdon *et al*., [@ref90]). Systematic reviews and meta-analyses have indicated that some typical antipsychotics (Schneider *et al*., [@ref79]; Lanctot *et al*., [@ref57]), atypical antipsychotics (Ballard and Waite, [@ref4]; Schneider *et al*., [@ref81]), and antidepressants (Seitz *et al*., [@ref84]) may have benefits in treating certain NPS, although the magnitude of benefit may be limited and potentially outweighed by adverse events. Atypical antipsychotics, the most extensively studied and utilized medications for NPS, are also associated with serious adverse events such as death (Schneider *et al*., [@ref78]; Wang *et al*., [@ref108]; Gill *et al*., [@ref36]) or stroke (Herrmann *et al*., [@ref41], Gill *et al*., [@ref35]), as well as falls (Hien Le *et al*., [@ref43]), sedation (Schneider *et al*., [@ref80]), and cognitive decline (Schneider *et al*., [@ref80]; Vigen *et al*., [@ref107]). Although there has been a decline in the use of antipsychotics with dementia recently, these medications continue to be used frequently (Kales *et al*., [@ref51]). The safety of other medications used to treat NPS in LTC has also been questioned (Huybrechts *et al*., [@ref48]).

Although there are previous reviews on the use of psychotropic medications for the management of NPS (Schneider *et al*., [@ref79]; [@ref81]; Borson and Raskind, [@ref14]; Lanctot *et al*., [@ref57]; Sutor *et al*., [@ref95]; Kindermann *et al*., [@ref53]; Snowden *et al*., [@ref89]; Alexopoulos *et al*., [@ref1]; Bharani and Snowden, [@ref13]; Sink *et al*., [@ref88]; Ballard and Howard, [@ref3]; Kozman *et al*., [@ref55]; Herrmann and Lanctot, [@ref40]; Konavalov *et al*., [@ref54]; Saddichha and Pandey, [@ref77]; Ballard *et al*., [@ref8]; [@ref9]; Conn and Seitz, [@ref25]; Gauthier *et al*., [@ref33]), few have focused exclusively on studies conducted in LTC settings (Snowden *et al*., [@ref89]; Bharani and Snowden, [@ref13]). Residents of LTC facilities with dementia may be particularly susceptible to adverse events associated with psychotropics when compared with community or hospital-based populations. Controlled trials and observational studies of older adults with dementia have indicated that LTC residents have more advanced age, more severe cognitive impairment, higher rates of comorbidity (Schneider *et al*., [@ref80]; Gill *et al*., [@ref36]; Rochon, [@ref74]), and receive lower quality of routine and preventative care (Fahey *et al*., [@ref30]) than outpatient or hospital populations. In addition, higher rates of mortality have been observed for LTC residents with dementia newly started on antipsychotics when compared with community-dwelling populations (Gill *et al*., [@ref36]; Rochon *et al*., [@ref74]). For these reasons, LTC residents may be particularly susceptible to mortality and other adverse events associated with psychotropic use which may have been underestimated in previous reviews which included both LTC and other populations within the same review. Also, some reviews have included both randomized and non-randomized studies (Bharani and Snowden, [@ref13]). Importantly, only a few previous reviews have assessed the quality of studies (Schneider *et al*., [@ref80]). Therefore, the objectives of this study were to provide a systematic review of randomized controlled trials (RCTs) for pharmacological treatments of NPS conducted specifically in LTC settings and evaluate the efficacy, and safety of treatments as well as the quality of studies.

Methods {#sec2}
=======

Search strategy {#sec2-1}
---------------

Standard guidelines for conducting systematic reviews were used to guide the review process (Moher *et al*., [@ref63]). We searched the electronic databases Medline, EMBASE, and PsychINFO (January 1980--February 2011), and the Cochrane Library using free text and medical subject headings to identify relevant articles (see Box 1, available as supplementary material attached to the electronic version of this paper at [www.journals.cambridge.org/jid_IPG](www.journals.cambridge.org/jid_IPG)). Google Scholar was also searched for additional articles using key words and citation lists. Hand-searches of reference lists of retrieved articles, previous reviews, and guidelines (Canadian Coalition for Seniors' Mental Health, [@ref17]) were used to supplement the electronic database search.

Study selection {#sec2-2}
---------------

The titles and abstracts of citations from electronic databases were independently reviewed by two study authors. Full-text articles were then reviewed for inclusion criteria. Randomized, parallel-group, controlled trials comparing any pharmacological intervention to placebo, another medication, or non-pharmacological interventions were included. We only included studies where NPS was the primary study outcome. We included studies reporting overall levels of NPS using composite measures of NPS on commonly utilized rating scales (e.g. Neuropsychiatric Inventory) or on specific measures of agitation, psychosis, or aggression. Studies that only evaluated depression or apathy in LTC residents with dementia were excluded. We excluded uncontrolled pre--post studies and crossover designs given the high-placebo response rate observed in some studies (Schneider *et al*., [@ref80]). Study populations had to be exclusively from LTC or where LTC residents formed the majority (\>50%) of participants. All English-language publications that provided sufficient detail for data extraction were included. Full-text articles were reviewed for inclusion criteria by two study authors with discrepancies resolved through discussion.

Data extraction {#sec2-3}
---------------

We extracted the following information from studies: dose of medication, number of participants, gender distribution, number and location of LTC facilities, dementia severity, method for diagnosing dementia, and study duration. We categorized studies according to pharmacological class. Baseline severity of NPS and change in NPS as reported on NPS rating scales (e.g. Cohen-Mansfield Agitation Inventory) were recorded. For dichotomous outcomes (e.g. number of individuals with a treatment response), the number of individuals with the outcome was recorded. For studies that did not report a primary outcome, we selected the change in NPS symptom rating scale total score as measured at study endpoint as the primary measure of efficacy. Safety and tolerability outcomes included: rates of trial withdrawals due to any cause, trial withdrawals due to adverse events, and mortality. All data were extracted in duplicate by two study authors using a standard data extraction form and discrepancies were resolved through further discussion.

Study quality {#sec2-4}
-------------

The Cochrane collaboration risk of bias assessment tool was utilized to describe the potential risk of bias associated with various aspects of study design (Higgins and Green, [@ref44]). This tool evaluates the following properties of studies: method of random sequence generation, concealment of allocation, blinding, incomplete outcome data, selective outcome reporting, and other potential sources of bias including sponsorship bias (i.e. whether the funding source could have led to a potential financial conflict of interest). Each item was rated as being potentially at low risk of bias ("Yes"), high risk of bias ("No"), or unclear. All items were rated in duplicate by two authors.

Data synthesis {#sec2-5}
--------------

Information on study characteristics, assessment of study quality, and efficacy and safety outcomes was summarized in tables. We summarized the effects of pharmacological interventions by medication class. The studies that reported on both antipsychotics and another active comparator were described in the non-antipsychotic category (e.g. studies comparing antipsychotics and cholinesterase inhibitors were described under the cholinesterase inhibitor section).

Results {#sec3}
=======

Study selection {#sec3-1}
---------------

The flow of studies through the review process is summarized in [Figure 1](#fig1){ref-type="fig"}. A total of 8,342 citations were identified through searches of electronic databases and 315 full-text articles were retrieved and reviewed. From these articles, 29 studies were identified that met our inclusion criteria. Figure 1.Flow of studies through the review process.

Characteristics of included studies {#sec3-2}
-----------------------------------

The 29 studies meeting inclusion criteria encompassed 19 studies of antipsychotics (Barnes *et al*., [@ref12]; Cantillon *et al*., [@ref18]; De Deyn *et al*., [@ref27]; [@ref28]; Katz *et al*., [@ref52]; Street *et al*., [@ref92]; Gaber *et al*., [@ref32]; Brodaty *et al*., [@ref15]; Fontaine *et al*., [@ref31]; Ballard *et al*., [@ref6]; Mintzer *et al*., [@ref61]; [@ref62]; Tariot *et al*., [@ref100]; Verhey *et al*., [@ref105]; Holmes *et al*., [@ref45]; Huertas *et al*., [@ref47]; Zhong *et al*., [@ref111]; Streim *et al*., [@ref93]; Rappaport *et al*., [@ref71]) (15 studies of atypical antipsychotics (De Deyn *et al*., [@ref27]; [@ref28]; Katz *et al*., [@ref52]; Street *et al*., [@ref92]; Brodaty *et al*., [@ref15]; Fontaine *et al*., [@ref31]; Ballard *et al*., [@ref6]; Mintzer *et al*., [@ref61]; [@ref62]; Tariot *et al*., [@ref100]; Verhey *et al*., [@ref105]; Holmes *et al*., [@ref45]; Zhong *et al*., [@ref111]; Streim *et al*., [@ref93]; Rappaport *et al*., [@ref71]) and seven of typical antipsychotics (Barnes *et al*., [@ref12]; Cantillon *et al*., [@ref18]; De Deyn *et al*., [@ref27]; Gaber *et al*., [@ref32]; Tariot *et al*., [@ref100]; Verhey *et al*., [@ref105]; Huertas *et al*., [@ref47])), three studies of cholinesterase inhibitors (Tariot *et al*., [@ref98]; Ballard *et al*., [@ref6]; Holmes *et al*., [@ref45]), four studies of anticonvulsants (Tariot *et al*., [@ref97]; [@ref99]; Porsteinsson *et al*., [@ref70]; Sommer *et al*., [@ref91]), one study of antidepressants (Gaber *et al*., [@ref32]), and seven studies evaluating medications from other classes (Cantillon *et al*., [@ref18]; Kyomen *et al*., [@ref56]; Hall *et al*., [@ref38]; Peskind *et al*., [@ref66]; Huertas *et al*., [@ref47]; Gehrman *et al*., [@ref34]; Wang *et al*., [@ref109]) ([Table 1](#tab1){ref-type="table"}). Of these studies, 20 were placebo-controlled (Barnes *et al*., [@ref12]; Tariot *et al*., [@ref97]; [@ref98]; [@ref99]; De Deyn *et al*., [@ref27]; [@ref28]; Katz *et al*., [@ref52]; Kyomen *et al*., [@ref56]; Street *et al*., [@ref92]; Porsteinsson *et al*., [@ref70]; Brodaty *et al*., [@ref15]; Ballard *et al*., [@ref6]; Hall *et al*., [@ref38]; Peskind *et al*., [@ref66]; Mintzer *et al*., [@ref61]; [@ref62]; Tariot *et al*., [@ref100]; Zhong *et al*., [@ref111]; Streim *et al*., [@ref93]; Gehrman *et al*., [@ref34]; Rappaport *et al*., [@ref71]; Sommer *et al*., [@ref91]; Wang *et al*., [@ref109]), and 11 compared two medications within the same trial (Barnes *et al*., [@ref12]; Cantillon *et al*., [@ref18]; De Deyn *et al*., [@ref27]; Gaber *et al*., [@ref32]; Fontaine *et al*., [@ref31]; Ballard *et al*., [@ref6]; Tariot *et al*., [@ref100]; Verhey *et al*., [@ref105]; Holmes *et al*., [@ref45]; Huertas *et al*., [@ref47]). All of the studies used oral formulations of medications except for one trial that utilized intramuscular aripiprazole (Rappaport *et al*., [@ref71]) and one study of transdermal estrogen (Hall *et al*., [@ref38]). A total of 4,954 individuals were included with a median study sample size of 76 (range = 14--625 participants per trial). The median age of participants in studies was 83 years and 71% were women in studies reporting the gender distribution. Most study participants had moderate to severe dementia with average Mini-Mental State Examination (MMSE) scores of between 5 and 14. The median trial duration was 56 days (range = 1--90 days). A variety of outcome measures were reported in studies including composite measures of NPS (Barnes *et al*., [@ref12]; Cantillon *et al*., [@ref18]; Tariot *et al*., [@ref97]; [@ref98]; [@ref99]; [@ref100]; De Deyn *et al*., [@ref27]; [@ref28]; Katz *et al*., [@ref52]; Street *et al*., [@ref92]; Porsteinsson *et al*., [@ref70]; Fontaine *et al*., [@ref31]; Peskind *et al*., [@ref66]; Gehrman *et al*., [@ref34]; Sommer *et al*., [@ref91]; Wang *et al*., [@ref109]), agitation (Gaber *et al*., [@ref32]; Ballard *et al*., [@ref6]; Verhey *et al*., [@ref105]; Holmes *et al*., [@ref45]; Zhong *et al*., [@ref111]; Rappaport *et al*., [@ref71],), aggression (Kyomen *et al*., [@ref56]; Brodaty *et al*., [@ref15]; Hall *et al*., [@ref38]; Huertas *et al*., [@ref47]), or psychosis (Mintzer *et al*., [@ref61]; [@ref62]; Streim *et al*., [@ref93]). Table 1.Included studies of pharmacological interventions for long-term care residents with dementia[intervention]{.smallcaps}[number]{.smallcaps}[age, mean (sd)]{.smallcaps}[female gender, n (%)]{.smallcaps}[setting and duration]{.smallcaps}[dementia diagnosis, average mmse scores]{.smallcaps}[outcome measure]{.smallcaps}[change in nps]{.smallcaps}[percentage of trial withdrawals/ withdrawal due to adverse events/ mortality]{.smallcaps}[comment]{.smallcaps}AntipsychoticsBarnes *et al*. ([@ref12])Loxapine 10.5 mg/day1983--LTC in the USADSM-IIIBPRS total--43.3/--/--All groups significantlyThioridazine 62.5 mg/day17----8 weeks------/--/--different from baseline but noPlacebo17----------/--/--difference between groups.De Deyn *et al*. ([@ref27])Risperidone 0.5--4 mg/day (mean = 1.1 mg/day)1158165 (56.5)51 LTC, 8 countriesDSM-IV, 6.3--8.6BEHAVE-AD total−5.240.9/--/--Individuals completing 12 weeks of risperidone were improved compared with placebo.Haloperidol 0.54 mg/day (mean = 1.2 mg/day)1158262 (53.9)12 weeks−6.630/--/--Placebo1148167 (58.8)−4.235.1/--/--Katz *et al*. ([@ref52])Risperidone 0.5 mg/day14983.2 (7.9)108 (72.5)LTC hospital in the USADSM-IV, 6.3--7.7BEHAVE-AD total−4.821.5/8.1/4.8Risperidone 1.0 mg/day14883.1 (7.2)98 (66.2)−6.5\*30.4/16.2/8.8\*Risperidone 2.0 mg/day16582.0 (78)108 (65.5)12 weeks−6.4\*41.8\*/24.2\*/3.6Placebo16382.6 (7.7)110 (67.5)−4.227/12.3/3.1Street *et al*. ([@ref92])Olanzapine 5 mg5682.9 (6.5)33 (58.9)28 LTC in the USANINCDS--ADRDA,NPI−7.6\*19.6/10.7/0NPI core consisting of agitation/ aggression, delusions, and hallucinations.Olanzapine 10 mg5083.6 (6.5)33 (66.0)−6.1\*28.0/8.0/0Olanzapine 15 mg5383.0 (6.7)31 (58.5)6 weeks6.4--7.3−4.934.0/17.0\*/0Placebo4781.4 (6.7)29 (61.7)−3.723.4/4.3/0Brodaty *et al*. ([@ref15])Risperidone 0.5--2 mg/day (mean = 0.95 mg/day)15383.2 (0.5)109 (71)14 LTC sites in Australia and New ZealandDSM-IV, AD, vascular, mixed 5.1--5.8CMAI--total aggression−7.5\*26.9/13.2/3.6BEHAVE-AD score also improved with risperidone.Placebo15682.7 (0.6)113 (72)−3.132.9/8.2/2.4Fontaine *et al*. ([@ref31])Olanzapine 2.5--10 mg (mean 6.6 mg/day)2083.3 (5.7)12 (60)LTC in the USADSM-IV, dementiaNPI−1520/20/0Both groups improved, no difference between groups.Risperidone 0.5--2 mg (mean 1.5 mg/day)1983.0 (9.4)14 (74)12 weeks7.2--9.3−23.632.9/8.2/2.4De Deyn *et al*. ([@ref28])Olanzapine 1 mg/day12876.6 (10.4)489 (75)LTC or continuing-care hospitals in Europe, Australia, Israel, Lebanon, South Africa 10 weeksNINCDS--ADRDA, DSM-IV-TR, AD 13.7 (5.1)NPI--NH total−14.8−15.7Olanzapine 2.5 mg/day134----Olanzapine 5 mg/day123----−16.3Olanzapine 7.5 mg/day Placebo128----−17.7\*−13.7Mintzer *et al*. ([@ref61])Risperidone 0.5--1.5 mg daily (mean = 1.0 mg/day)20283.4 (7.0)152 (75.2)44 LTC 8 weeksAD 13.1--13.2BEHAVE-AD Psychosis−2.925.5/10.6/0.8Placebo21483.3 (7.43)163 (76.2)−2.324.8/10.1/0Tariot *et al*. ([@ref100])Quetiapine 100 mg/day9181.9 (6.9)66 (73)47 LTC in the USA 10 weeksDSM-IV, NINCDS--ADRDA, AD, vascular, alcohol 12.4--13.2BPRS total−9.131.9/11.0/0Haloperidol 2.5 mg/day9483.5 (6.1)63 (67)−7.141.5/18.1/1.1Placebo9983.9 (6.7)79 (80)−6.736.4/13.1/0Verhey *et al*. ([@ref105])Olanzapine 2.5--7.5 mg/day (mean = 4.7 mg)3082.4 (5.5)17 (56.7)4 LTC and 2 outpatient sites in the Netherlands 5 weeksDSM-IV, dementia 10.0--10.9CMAI total Score−10.115.5/--/--Both groups improved, no difference between groups.Haloperidol 1--3 mg/day (mean = 1.7 mg/day)2883.3 (8.1)16 (57.1)−16.6--/--/--Mintzer *et al*. ([@ref62])Aripiprazole 2 mg/day11883.08181 LTC residential-assisted living facilities in the USA, Australia, Canada, South Africa, and Argentina 10 weeksDSM-IV, AD 12.4NPI--NH Psychosis--34.7/7.6/3.4Aripiprazole 5 mg/day12282.476--40.2/18/2.5Aripiprazole 10 mg/day12682.376−6.945.2/24.6\*/6.3Placebo12182.282−5.146.3/13.2/2.5Zhong *et al*. ([@ref111])Quetiapine 200 mg/day11783.5 (8.0)92 (78.6)53 LTC and assisted living in the USA 10 weeksDSM-IV, NINCDS-ADRDA, possible or probable AD, vascular 4.8--5.6PANSS-EC−4.934.7/8.1/7.3Quetiapine 100 mg/day12483.0 (7.2)90 (72.6)−5.736.8/14.5/5.1Placebo9283.2 (7.2)65 (70.7)−3.934.8/9.8/3.3Streim *et al*. ([@ref93])Aripiprazole 2--15 mg/day (mean = 9 mg/day)13183.074 (56.5)NH or residential assisted-living facilities in the USA 10 weeksDSM-IV, AD 13.9 (8.6)NPI--NH Psychosis−4.530.4\*/12.8/2.4CMAI and NPI total score decreased significantly in treatment compared with placebo.Placebo12583.078 (62.4)13.3 (8.9)−4.649.0/8.4/2.3Rappaport ([@ref71])Aripiprazole 2.5--5 mg IM1280.2 (5.4)8 (67)16 LTC in the USADSM-IV, AD, vascular, mixedPANSS-EC−40/0/0Rappaport *et al*. ([@ref71])Aripiprazole 5--10 mg IM7880.0 (10.3)50 (64)24 hours−70/1.3/0Aripiprazole 10--15 mg IM1379.9 (6.0)9 (69)−87.7/0/7.7Placebo2679.5 (7.8)16 (62)−53.8/0/0Cholinesterase inhibitorTariot *et al*. ([@ref98])Donepezil 10 mg10385.485 (83)27 LTC in the USA 24 weeksNINDS-ADRDA 14.4NPI--NH−2.318/11/3Placebo10585.986 (82)−4.926/18/6.6Ballard *et al*. ([@ref6])Rivastigmine 6--12 mg/day, Quetiapine 50--100 mg3184.3 (7.8)23 (74)LTC in the UK 6 weeksAD, dementia SIB:CMAI−5.141.9\*/16.1/6.5All treatments showed3184.2 (8.6)27 (87)58.8--69.0−4.032.2\*/6.5/6.5reduction in agitation scorePlacebo3183.0 (6.8)24 (77)−6.23.2/0/0after 6 weeks with no difference between groups.Holmes *et al*. ([@ref45])Rivastigmine 3--6 mg/day1587.0 (6.5)12 (80)LTC in the UKNINCDS--ADRDA, probable AD 6.3--9.0CMAI−1.9--/--/--Risperidone more effective than rivastigmine.Risperidone 0.5--1 mg/day1285.3 (5.0)8 (67)−24.8\*--/--/--AnticonvulsantTariot *et al*. ([@ref97])Carbamazepine 300 mg/day2787.1 (6.2)23 (85)4 LTC in USANINCDS-ADRDA, AD, vascular, mixed 3.9--8.3BPRS total−7.7\*14.8/3.7/0Placebo2484.8 (6.5)18 (75)6 weeks−0.90/0/0Porsteinsson *et al*. ([@ref70])Divalproex sodium 375 mg/day2885.3 (8.1)17 (61)7 LTC in the USADSM-IV, NINCDS--ADRDA, AD, vascular, mixed 6.7--7.0BPRS total−6.96.7/6.7/0No significant difference reported on CMAI.Placebo2884.7 (6.0)22 (79)6 weeks−5.912.5/12.5/0Tariot *et al*. ([@ref99])Divalproex sodium 800 mg/day7584.2 (6.6)48 (63)LTC in the USANINCDS--ADRDA, probable AD 10.5--10.8BPRS total−4.214.7/6.6/1.3Placebo7883.9 (5.9)57 (73)6 weeks−5.117.9/6.4/0Sommer *et al*. ([@ref91])Oxcarbazepine 300--900 mg/day528335 (67.3)35 LTC in NorwayICD-10, AD, vascular 5.4--6.2NPI--NH--28.8\*/21.1/0Change in score not reported but difference not statistically significant.Placebo518438 (74.5)8 weeks--9.8/7.9/0AntidepressantGaber *et al*. ([@ref32])Sertraline 25--50 mg/day1381.5 (6.7)--Institutionalized in Italy 10 weeksDSM-IV, dementia -- --CMAI−13--/--/--No significant differences from baseline to 10 weeks in either group.Haloperidol 1--2 mg/day10----−10--/--/--OtherCantillon *et al*. ([@ref18])Buspirone 5 mg TID1278.8 (5.1)8 (66.7)LTC in USANINCDS-ADRDA, probable AD 2.5--2.6BPRS total−6.7--/--/--Haloperidol 0.5 mg TID1479.6 (4.9)9 (64.3)10 weeks--/--/--Kyomen *et al*. ([@ref56])Estrogen 0.625--2.5 mg881.0 (3.7)7 (87.5)LTC in USADSM-III-R, dementia 4.1--5.5OAS+4.7\*0/0/0Placebo687.8 (8.27)5 (83.3)4 weeks+2.116.7/0/0Hall *et al*. ([@ref38])Estrogen transdermal patch, 50--100 mcg/day1378.1 (6.2)0 (0)LTC and psych inpatient ward, Australia 8 weeksDSM-IV, dementia 2.6--5.4RAGE\~2.5--/--/0Results reported as "no significant difference" on RAGE.Placebo1478.8 (9.6)0 (0)\~1--/--/0Peskind *et al*. ([@ref66])Propranolol 30--120 mg/day1786 (8)14 (82.4)1 NH in the USA 6 weeksNINCDS--ADRDA, probable AD 7. 2--7.8NPI−8.0\*35.3\*/0/0Placebo1484 (8)11 (78.6)−0.478.6/14.3/0Huertas *et al*. ([@ref47])Cyproterone 100 mg/day1479.9 (7.3)7 (50)LTC and outpatient in Spain 90 daysDSM-III-R, NINCDS--ADRDA, AD 6.8--6.9SOAS21.4/21.4/0Outcome was number of individuals with SOAS response.Haloperidol 2 mg/day1381.6 (6.9)12 (92.3)0/0/0Gehrman *et al*. ([@ref34])Melatonin 10 mg2482.9 (7.0)16 (68.3)NH in the USA 10 daysNINCDS--ADRDA, AD 5.8CMAI total--0/0/Difference not statistically significant. No difference noted on the ABRS scale.Placebo17------0/0/0Wang *et al*. ([@ref109])Prazosin 1--6 mg daily1183.2 (11.5)4 (36.4)1 NH in the USA 8 weeksNINCDS--ADRDA, probable or possible AD 9.3--12.0NPI−19\*41.6/--/0Prazosin also more effective on BPRS.Placebo1178.1 (10.8)5 (45.5)−250/--/0[^1][^2]

Efficacy of interventions on neuropsychiatric symptoms of dementia {#sec3-3}
------------------------------------------------------------------

The efficacy of pharmacological interventions for NPS is summarized in [Table 1](#tab1){ref-type="table"}.

### Antipsychotics {#sec3-3-1}

The 15 studies of atypical antipsychotics involved risperidone (N = 6), olanzapine (N = 4), quetiapine (N = 3), and aripiprazole (N = 3). Statistically significant results on change in NPS scores compared with placebo were noted in two studies of risperidone (Katz *et al*., [@ref52]; Brodaty *et al*., [@ref15]), two studies of olanzapine (Street *et al*., [@ref92]; De Deyn *et al*., [@ref28]), and one study of aripiprazole (Mintzer *et al*., [@ref62]). One study comparing risperidone and olanzapine found no statistically significant difference between the two groups (Fontaine *et al*., [@ref31]). Olanzapine and haloperidol were both associated with reductions in agitation and NPS with no significant differences between groups (Verhey *et al*., [@ref105]). Risperidone was associated with greater reductions in agitation when compared with rivastigmine in one study (Holmes *et al*., [@ref45]). One study also found no significant differences when either quetiapine or rivastigmine was compared with placebo (Ballard *et al*., [@ref6]). A trial of quetiapine, haloperidol, and placebo found no difference between either of the two active treatment groups and placebo in measures of NPS (Tariot *et al*., [@ref100]). A single trial compared the typical antipsychotics loxapine, thioridazine, and placebo and found no benefit for either medication over placebo (Barnes *et al*., [@ref12]).

Eight studies reported change in NPS using dichotomized outcomes. Risperidone was associated with overall clinical improvement in NPS when compared with placebo in two studies (Brodaty *et al*., [@ref15]; Mintzer *et al*., [@ref61]) and significant reduction in NPS in a second study (Katz *et al*., [@ref52]). However, a third study did not find any difference in response rates for risperidone compared with either haloperidol or placebo (De Deyn *et al*., [@ref27]). Olanzapine at doses of 5 and 10 mg daily were more likely to produce significant reductions in NPS when compared with placebo, although the 15 mg dose was not better than placebo (Street *et al*., [@ref92]). Aripiprazole was associated with a greater response rate than placebo in one study (Streim *et al*., [@ref93]), while a second study did not find any difference in response (Mintzer *et al*., [@ref62]). Quetiapine at 200 mg daily was found to be associated with a higher proportion of individuals with significant global improvement than placebo in one study, while 100 mg was not associated with significant benefit (Zhong *et al*., [@ref111]).

### Cholinesterase inhibitors {#sec3-3-2}

One study of donepezil found no benefit for the medication when compared with placebo on measures of NPS (Tariot *et al*., [@ref98]). Two studies evaluated the cholinesterase inhibitor rivastigmine (Ballard *et al*., [@ref6]; Holmes *et al*., [@ref45]), with there being no benefit for rivastigmine when compared with placebo (Ballard *et al*., [@ref6]), or the atypical antipsychotics quetiapine (Ballard *et al*., [@ref6]) or risperidone (Holmes *et al*., [@ref45]).

### Anticonvulsants {#sec3-3-3}

Of the four placebo-controlled studies involving anticonvulsants, one evaluated carbamazepine (Tariot *et al*., [@ref97]), two examined divalproex sodium (Porsteinsson *et al*., [@ref70]; Tariot *et al*., [@ref99]), and one study examined oxcarbazepine (Sommer *et al*., [@ref91]). Only carbamazepine was associated with a statistically significant reduction in NPS symptoms (Tariot *et al*., [@ref97]) while the other studies showed no benefit for other anticonvulsants compared with placebo (Porsteinsson *et al*., [@ref70]; Tariot *et al*., [@ref99]; Sommer *et al*., [@ref91]).

### Antidepressants {#sec3-3-4}

A single small study compared sertraline with haloperidol on NPS and found that both groups had a non-significant reduction in NPS with no difference between groups (Gaber *et al*., [@ref32]).

### Other medications {#sec3-3-5}

A study comparing buspirone and haloperidol found no significant difference between the two groups on symptoms of NPS (Cantillon *et al*., [@ref18]). Two placebo-controlled studies evaluated the effects of estrogen therapy on NPS, one with oral estrogen (Kyomen *et al*., [@ref56]) and a second with a transdermal estrogen patch (Hall *et al*., [@ref38]), with only the study in which estrogen was administered orally demonstrating benefit over placebo. A single trial of the androgen antagonist cyproterone acetate compared with haloperidol and found that cyproterone was associated with greater improvement in NPS (Huertas *et al*., [@ref47]). A placebo-controlled trial of the β-adrenergic antagonist propranolol demonstrated improvement in NPS symptoms scores and global improvement in NPS (Peskind *et al*., [@ref66]). One study of the α-1 adrenergic antagonist prazosin demonstrated benefits on NPS when compared with placebo (Wang *et al*., [@ref109]). A placebo-controlled study of melatonin did not demonstrate any benefit for NPS (Gehrman *et al*., [@ref34]).

Safety and tolerability {#sec3-4}
-----------------------

A total of 24 studies reported on trial withdrawals due to any cause (Tariot *et al*., [@ref97]; [@ref98]; [@ref99]; [@ref100]; De Deyn *et al*., [@ref27]; [@ref28]; Katz *et al*., [@ref52]; Kyomen *et al*., [@ref56]; Street *et al*., [@ref92]; Porsteinsson *et al*., [@ref70]; Brodaty *et al*., [@ref15]; Fontaine *et al*., [@ref31]; Ballard *et al*., [@ref6]; Peskind *et al*., [@ref66]; Mintzer *et al*., [@ref61]; [@ref62]; Huertas *et al*., [@ref47]; Streim *et al*., [@ref93]; Gehrman *et al*., [@ref34]; Rappaport *et al*., [@ref71]; Sommer *et al*., [@ref91]; Wang *et al*., [@ref109]), 21 studies reported on trial withdrawals due to adverse events (Tariot *et al*., [@ref97]; [@ref98]; [@ref99]; [@ref100]; Katz *et al*., [@ref52]; Kyomen *et al*., [@ref56]; Street *et al*., [@ref92]; Porsteinsson *et al*., [@ref70]; Brodaty *et al*., [@ref15]; Fontaine *et al*., [@ref31]; De Deyn *et al*., [@ref28]; Ballard *et al*., [@ref6]; Peskind *et al*., [@ref66]; Mintzer *et al*., [@ref61]; [@ref62]; Huertas *et al*., [@ref47]; Zhong *et al*., [@ref111]; Streim *et al*., [@ref93]; Gehrman *et al*., [@ref34]; Rappaport *et al*., [@ref71]; Sommer *et al*., [@ref91]), and 23 studies reported mortality rates (Tariot *et al*., [@ref97]; [@ref98]; [@ref99]; [@ref100]; Katz *et al*., [@ref52]; Kyomen *et al*., [@ref56]; Street *et al*., [@ref92]; Porsteinsson *et al*., [@ref70]; Brodaty *et al*., [@ref15]; Fontaine *et al*., [@ref31]; De Deyn *et al*., [@ref28]; Ballard *et al*., [@ref6]; Hall *et al*., [@ref38]; Peskind *et al*., [@ref66]; Mintzer *et al*., [@ref61]; [@ref62]; Huertas *et al*., [@ref47]; Zhong *et al*., [@ref111]; Streim *et al*., [@ref93]; Gehrman *et al*., [@ref34]; Rappaport *et al*., [@ref71]; Sommer *et al*., [@ref91]; Wang *et al*., [@ref109]) ([Table 1](#tab1){ref-type="table"}). Trial withdrawals due to any cause or adverse events were common in many studies. One risperidone trial found that the 2 mg dose was associated with higher rates of overall trial withdrawals and trial withdrawals due to adverse events compared with placebo, while mortality was higher with 1 mg daily when compared with placebo (Katz *et al*., [@ref52]). Olanzapine at 15 mg daily was associated with higher rates of withdrawal due to adverse events although lower doses were not significantly different from placebo (Street *et al*., [@ref92]). Only the 10 mg dose of aripiprazole was associated with an increased risk of adverse events when compared with placebo in one study (Mintzer *et al*., [@ref62]), while a second of aripiprazole found that overall rates of trial withdrawal were higher with aripiprazole (Streim *et al*., [@ref93]). Both quetiapine and rivastigmine were associated with higher rates of withdrawal than placebo in one study (Ballard *et al*., [@ref6]) as was oxcarbazepine when compared with placebo (Sommer *et al*., [@ref91]). One study of propranolol found lower rates of trial withdrawals associated with drug treatment when compared with placebo (Peskind *et al*., [@ref66]).

Quality of studies {#sec3-5}
------------------

In general, most studies were rated as being at low or unclear risk of bias due to various aspects related to study design ([Table 2](#tab2){ref-type="table"}). Only one study was rated as being at low risk of bias on all the risk of bias items (Ballard *et al*., [@ref6]). For the assessment of potential risk of bias associated with the study sponsor, 14 studies were funded by pharmaceutical companies, including 12 studies sponsored by the manufacturers of atypical antipsychotics (De Deyn *et al*., [@ref27]; [@ref28]; Katz *et al*., [@ref52]; Street *et al*., [@ref92]; Brodaty *et al*., [@ref15]; Fontaine *et al*., [@ref31]; Mintzer *et al*., [@ref61]; [@ref62]; Tariot *et al*., [@ref100]; Zhong *et al*., [@ref111]; Streim *et al*., [@ref93]; Rappaport *et al*., [@ref71]), one study of typical antipsychotics (Barnes *et al*., [@ref12]), and one study of cholinesterase inhibitors (Tariot *et al*., [@ref98]). Table 2.Risk of bias assessment for pharmacological treatment of neuropsychiatric symptoms of dementia[sequence generation]{.smallcaps}[allocation concealment]{.smallcaps}[blinding]{.smallcaps}[incomplete outcome data]{.smallcaps}[selective outcome reporting]{.smallcaps}[other -- funding source]{.smallcaps}AntipsychoticBarne*s et al*. ([@ref12])UnclearUnclearUnclearYesYesNoDe Deyn *et al*. ([@ref27])YesYesUnclearYesYesNoKatz *et al*. ([@ref52])YesUnclearYesUnclearYesNoStreet *et al*. ([@ref92])UnclearUnclearUnclearYesYesNoBrodaty *et al*. ([@ref15])YesUnclearYesYesYesNoFontaine *et al*. ([@ref31])UnclearUnclearUnclearNoYesNoDe Deyn *et al*. ([@ref28])UnclearUnclearUnclearYesYesNoMintzer *et al*. ([@ref61])UnclearYesUnclearUnclearYesNoTariot *et al*. ([@ref100])UnclearUnclearUnclearYesYesNoVerhey *et al*. ([@ref105])UnclearUnclearUnclearYesYesYesMintzer *et al*. ([@ref62])UnclearUnclearUnclearYesYesNoZhong *et al*. ([@ref111])YesUnclearUnclearYesYesNoStreim *et al*. ([@ref93])UnclearUnclearUnclearYesYesNoRappaport *et al*. ([@ref71])UnclearUnclearUnclearYesNoNoCholinesterase inhibitorsTariot *et al*. ([@ref98])YesUnclearYesYesYesNoBallard *et al*. ([@ref6])YesYesYesYesYesYesHolmes *et al*. ([@ref45])UnclearUnclearYesYesYesYesAnticonvulsantTariot *et al*. ([@ref97])UnclearUnclearYesYesYesYesPorsteinsson *et al*. ([@ref70])UnclearUnclearYesYesYesYesTariot *et al*. ([@ref99])YesYesUnclearYesYesYesSommer *et al*. ([@ref91])UnclearUnclearUnclearYesYesYesAntidepressantGaber *et al*. ([@ref32])UnclearUnclearYesUnclearYesYesOtherCantillon *et al*. ([@ref18])UnclearUnclearYesYesYesUnclearKyomen *et al*. ([@ref56])UnclearYesUnclearYesYesYesHall *et al*. ([@ref38])UnclearUnclearUnclearYesYesYesPeskind *et al*. ([@ref66])YesUnclearYesYesYesYesHuertas *et al*. ([@ref47])UnclearUnclearUnclearYesYesYesGehrman *et al*. ([@ref34])UnclearUnclearYesUnclearYesYesWang *et al*. ([@ref109])YesUnclearYesYesYesYes

Discussion {#sec4}
==========

Our review identified a number of RCTs evaluating a variety of medications for the management of NPS in LTC settings. Overall, the most frequently studied class of medications was atypical antipsychotics. There is some evidence to support the efficacy of the atypical antipsychotics risperidone, olanzapine, and aripiprazole when compared with placebo on change in NPS symptom scores. There were additional single small positive studies with carbamazepine, estrogen, cyproterone acetate, propranolol, and prazosin. The effects of medications tended to be clinically modest and only a few studies reported on the rates of clinically significant outcomes such as symptom remission. Some medications may be effective in reducing overall levels of NPS and specific NPS including agitation and aggression. The risk of bias for these studies varied, although many studies had some potentially important methodological limitations. Trial withdrawals, adverse events, and mortality were relatively common outcomes in many studies. Importantly, there were no studies comparing pharmacological agents to non-pharmacological approaches and a limited number of studies directly comparing different pharmacological agents.

The findings of our review of pharmacological treatments for NPS in LTC are consistent with previous broader reviews of antipsychotics and other medications for the treatment of NPS (Schneider *et al*., [@ref79]; [@ref81]; Borson and Raskind, [@ref14]; Lanctot *et al*., [@ref57]; Sutor *et al*., [@ref95]; Kindermann *et al*., [@ref53]; Snowden *et al*., [@ref89]; Alexopoulos *et al*., [@ref1]; Sink *et al*., [@ref88]; Ballard and Howard, [@ref3]; Kozman *et al*., [@ref55]; Herrmann and Lanctot, [@ref40]; Konavalov *et al*., [@ref54]; Saddichha and Pandey, [@ref77]; Ballard *et al*., [@ref8]; [@ref9]; Conn and Seitz, [@ref25]). The atypical antipsychotics (in particular risperidone, olanzapine, and aripiprazole) appear to have the most extensive evidence in favor of their use for NPS, although even this evidence is limited to a relatively small number of studies. There was only one study that directly compared two atypical antipsychotics with no statistically significant difference in NPS outcomes when comparing risperidone with olanzapine (Fontaine *et al*., [@ref31]). Results from a large RCT comparing olanzapine, risperidone, quetiapine, and placebo for outpatients with Alzheimer\'s disease found that the primary outcome of time to discontinuation of treatment due to any cause did not differ between any of the three active treatment groups compared with placebo. However, time to discontinuation due to lack of efficacy favored both risperidone and olanzapine in this study (Schneider *et al*., [@ref81]). While most studies evaluated the effects of atypical antipsychotics on overall change in NPS, they appear to be most effective in reducing particular symptoms such as hostility, anger, and psychosis (Sultzer *et al*., [@ref94]). Although statistically significant results were observed in several studies in our review, clinically significant outcomes such as response rates or global clinical impression of change were only reported in a few studies.

Although there were few statistically significant differences noted on most safety outcomes, this is likely due to the limited power of many studies to detect adverse events associated with therapies. Existing meta-analyses and observational studies have however demonstrated major safety concerns with the use of atypical antipsychotics and other medications for NPS. Meta-analyses have demonstrated that atypical antipsychotics are associated with an increased risk of death (Schneider *et al*., [@ref78]) with an odds ratio of 1.54, and an absolute risk difference of approximately 1% from studies conducted in LTC and other settings. Observational studies have also found an increased risk of mortality (Gill *et al*., [@ref36]). Similarly, an increased risk of major cerebrovascular events associated with antipsychotics use has been observed in meta-analyses of RCTs (Herrmann and Lanctot, [@ref39]), with a relative risk of 2.7 and an absolute risk difference of approximately 1%. Other less serious, but more common side effects associated with atypical antipsychotics include increased rates of somnolence (Schneider *et al*., [@ref80]), falls (Hien Le *et al*., [@ref43]), and fall-related injuries including hip fractures (Jalbert *et al*., [@ref49]), which must also be monitored during therapy. There is also an increasing appreciation of the effects of atypical antipsychotics on cognitive and functional decline in older adults with dementia (Vigen *et al*., [@ref107]).

There were relatively few studies that examined medications other than atypical antipsychotics. Some typical antipsychotics may also be effective for NPS (Schneider *et al*., [@ref79]; Lanctot *et al*., [@ref57]), although these medications are no more effective than atypical antipsychotics and are associated with higher rates of adverse events (De Deyn *et al*., [@ref27]; Verhey *et al*., [@ref105]; Tariot *et al*., [@ref100]). The risk of death (Wang *et al*., [@ref108]; Gill *et al*., [@ref36]) and stroke (Herrmann *et al*., [@ref41]; Gill *et al*., [@ref35]) associated with typical antipsychotics is similar to or greater than the risk observed with atypical antipsychotics. There was only a single small study of antidepressants for NPS conducted in LTC, although there is growing interest in the use of antidepressants for this indication (Seitz *et al*., [@ref84]). Recent RCTs of the antidepressant citalopram and escitalopram have indicated that these medications may be as effective as the antipsychotics risperidone (Pollock *et al*., [@ref69]) or perphenazine (Pollock *et al*., [@ref68]) and more effective than placebo (Pollock *et al*., [@ref68]) in hospitalized inpatient populations. Importantly, the rates of adverse events with antidepressants may be less than that observed with antipsychotics (Pollock *et al*., [@ref69]; Barak *et al*., [@ref11]). However, serotonergic antidepressants have been associated with serious adverse events in older adults including falls (Vestergaard *et al*., [@ref106]), fractures (Takkouche *et al*., [@ref96]), bleeding (Andrade *et al*., [@ref2]), and hyponatremia (Fabian *et al*., [@ref29]). Some observational studies have also reported that antidepressants may be associated with an increased risk of death (Huybrechts *et al*., [@ref48]) and stroke (Trifiro *et al*., [@ref102]; Wu *et al*., [@ref110]), although not all studies have confirmed these associations (Kales *et al*., [@ref50]). The anticonvulsant carbamazepine demonstrated benefit in terms of reduction of agitation in a single small study conducted in LTC (Tariot *et al*., [@ref97]) as well as two other small trials conducted outside of LTC (Cooney *et al*., [@ref26]; Olin *et al*., [@ref65]). Other medications reporting benefit were represented by single small studies and these agents may be considered for some individuals who do not tolerate or fail to respond to other treatments, although further research is needed to establish their efficacy and safety. Divalproex sodium was not effective at reducing NPS in studies included in our review (Porsteinsson *et al*., [@ref70]; Tariot *et al*., [@ref99]) and other studies have demonstrated that valproic acid may accelerate cognitive decline (Tariot *et al*., [@ref101]) and, as such, these medications should be avoided in patients with NPS. Studies of cholinesterase inhibitors for the treatment of NPS did not find that these medications were effective in reducing NPS among patients with significant symptoms (Tariot *et al*., [@ref98]; Ballard *et al*., [@ref6]; Holmes *et al*., [@ref45]), which has also been observed in trials conducted in community-based populations (Howard *et al*., [@ref46]).

Although most of the trials in our review were between 6 and 12 weeks in length, in clinical practice antipsychotics are often prescribed for prolonged periods of time in LTC (Ballard *et al*., [@ref5]; Ruths *et al*., [@ref75]; Gill *et al*., [@ref36]). The risk of adverse events associated with antipsychotics are greatest after initiating treatment (Gill *et al*., [@ref36]), although chronic therapy is also associated with risks (Ballard *et al*., [@ref7]). A placebo-controlled trial comparing continuation of antipsychotic therapy to placebo for LTC residents with NPS found that a decreased risk of mortality was associated with cessation of antipsychotics when compared with continued use (Ballard *et al*., [@ref10]). Discontinuation of antipsychotic therapy did not result in worsening of NPS for most individuals (Ballard *et al*., [@ref7]). Additional RCTs have demonstrated that antipsychotics can be discontinued in the majority of individuals receiving chronic antipsychotic therapy without worsening of behavior (Cohen-Mansfield *et al*., [@ref22]; van Reekum *et al*., [@ref104]; Ballard *et al*., [@ref5]; Ruths *et al*., [@ref75]; [@ref76]). Predictors of successful discontinuation of therapy include lower baseline severity of NPS (Ballard *et al*., [@ref5]; [@ref7]) and lower dosages of antipsychotics to achieve symptom control (van Reekum *et al*., [@ref104]; Ruths *et al*., [@ref76]).

There are some limitations to our review. One limitation relates to the method by which NPS were assessed, that being by retrospective questionnaire ratings of NPS as reported by nursing staff or other caregivers. Direct observations of behaviors would be considered the "gold standard" method for measuring NPS although studies have demonstrated that directly observed levels of agitation and questionnaire reported agitation are only moderately correlated (Cohen-Mansfield and Libin, [@ref20]). However, direct measures of NPS are too labor intensive to be used as outcome measures in large clinical studies and questionnaire reports of behavior are more feasible to use in this setting. We only focused on published English-language studies and there are additional unpublished studies that have been identified (Schneider *et al*., [@ref80]), which may have introduced a publication bias in favor of studies showing benefits with medications (Turner *et al*., [@ref103]). Many of the studies in our review were sponsored by pharmaceutical companies and studies that are sponsored by pharmaceutical companies are more likely to report outcomes in favor of the company\'s product than studies funded by other sources (Lexchin *et al*., [@ref59]). Finally, due to the range of medications, outcome measures, and clinical populations, we did not undertake meta-analysis to quantitatively summarize the effects of medications.

Particular strengths of our review should be highlighted. First, we restricted our review to randomized controlled clinical trials to evaluate only the highest level of evidence. We also included only those studies conducted in LTC settings and so the results observed should be generalizable to other LTC populations. Our review also assessed the quality of included studies to identify potential sources of bias which may influence the internal validity of the primary studies. Finally, we undertook a detailed examination of the efficacy and safety of medications to allow clinicians to better appreciate and communicate the potential benefits and risks of various treatments.

Conclusions {#sec5}
===========

The best supported evidence for management of NPS in LTC is for some atypical antipsychotics in particular risperidone, olanzapine, and aripiprazole. There are relatively few studies of other medications which have sufficient evidence base to support their use. However, the known risks of adverse events associated with antipsychotics and other psychotropic medications in LTC highlight the need for safe and effective alternatives to antipsychotics and existing pharmacological treatments. Non-pharmacological interventions should continue to be used as initial treatments for NPS where these are available, also taking into consideration patient and caregivers priorities. Further research into the comparative effectiveness of pharmacological treatments and non-pharmacological treatments is required to further understand the relative risks and benefits of treatments for NPS in LTC.
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[^1]: \*p \< 0.05 when compared with placebo or other comparator medication in the study; -- = not reported.

[^2]: ACES = Agitation--Calmness Evaluation Scale; AD = Alzheimer\'s disease; BEHAVE-AD = Behavioral Pathology in Alzheimer\'s Disease; BPRS = Brief Psychiatric Rating Scale; CGI = Clinical Global Impression; CMAI = Cohen-Mansfield Agitation Inventory; DSM = Diagnostic and Statistical Manual of Mental Disorders; ICD = International Classification of Disease; NH = nursing home; MMSE = Mini-Mental State Examination; NINCDS--ADRDA = National Institutes of Neurological and Communicative Disorders and Stroke -- Alzheimer\'s Disease and Related Disorders Association; NPI = Neuropsychiatric Inventory; OAS = Overt Aggression Scale; PANSS-EC = Positive and Negative Syndrome Scale -- Excited Component; RAGE = Rating Scale for Aggressive Behavior in the Elderly; SIB = Severe Impairment Battery; SOAS = Staff Observation Aggression Scale.
